Form 4: Ionis Director Michael Yang Acquires Shares via RSU Vesting

Ionis Pharmaceuticals Director Michael J. Yang acquired 1,930 shares of common stock through the vesting of Restricted Stock Units.

Summary

• Michael J. Yang, a Director at IONIS PHARMACEUTICALS INC (IONS), acquired 1,930 shares of common stock.
• The acquisition occurred on January 15, 2026, as a result of the vesting and release of a Restricted Stock Unit (RSU) award.
• Following this transaction, Mr. Yang directly beneficially owns 7,940 shares of common stock.
• Concurrently, 1,930 Restricted Stock Units were disposed of as they converted into common stock.
• After the transaction, Mr. Yang directly beneficially owns 7,150 Restricted Stock Units.
• Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock or its equivalent cash value.
• The Restricted Stock Units vest in three equal annual installments, with payment in whole shares or cash as determined by the Company.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-scheduled vesting of Restricted Stock Units, which is a neutral event in terms of company performance or strategic direction. It reflects standard compensation practices.

Positives

• The transaction increases the director's direct ownership of common stock, aligning interests with shareholders.

Future Outlook

The filing indicates that Restricted Stock Units vest in three equal annual installments, suggesting future scheduled vesting events for the remaining RSUs.

Industry Context

This is a routine insider transaction common in the biotechnology and pharmaceutical industry, where executive and director compensation often includes equity awards like Restricted Stock Units that vest over time.

Stakeholder Impact

• Shareholders: The transaction slightly increases the director's direct ownership, potentially aligning management and shareholder interests more closely.

Next Steps

• Future installments of the Restricted Stock Units are expected to vest annually, converting into common stock or cash as per company policy.

Key Dates

Keywords

IONIS PHARMACEUTICALS, IONS, Form 4, Insider Transaction, Restricted Stock Unit, RSU Vesting, Director Stock Acquisition, Beneficial Ownership